Alkermes EVP exercises options, sells 9K shares

Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 Ordinary Shares at an exercise price of $19.34 per share and acquired the related shares.

Rhea-AI Filing Summary

Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 Ordinary Shares at an exercise price of $19.34 per share and acquired the related shares. On the same date, he sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share in an open-market transaction.

Both the option exercise and the share sale were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 85,389 Ordinary Shares. The options exercised were fully vested in accordance with their terms, and no remaining derivative positions are shown in this filing.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Sold 9,000 shs ($320K)

Approx. gross sale proceeds $320K

Approx. exercise cost $97K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	5,000	$0.00	$0.00
Exercise	Ordinary Shares	5,000	$19.34	$97K
Sale	Ordinary Shares	9,000	$35.5116	$320K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 16,356 contracts (Direct); Ordinary Shares — 85,389 shares (Direct)

Footnotes (4)

1. F1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
2. F2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.50 to $35.62. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
4. F4. These options are fully vested in accordance with their terms.

Key Figures

Options exercised: 5,000 shares Exercise price: $19.34/share Shares sold: 9,000 shares +3 more

6 metrics

Options exercised 5,000 shares Employee Stock Options exercised at $19.34 on April 1, 2026

Exercise price $19.34/share Conversion price for 5,000 Employee Stock Options

Shares sold 9,000 shares Ordinary Shares sold in open market on April 1, 2026

Weighted average sale price $35.5116/share Sales executed between $35.50 and $35.62 per share

Shares held after transactions 85,389 shares Direct Ordinary Share holdings after exercise and sale

Rule 10b5-1 plan adoption date March 14, 2025 Governs the reported option exercise and share sale

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Buy), weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

fully vested financial

"These options are fully vested in accordance with their terms."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alkermes (ALKS) executive Craig C. Hopkinson report in this Form 4?

Craig C. Hopkinson reported exercising stock options for 5,000 Ordinary Shares and selling 9,000 Ordinary Shares. Both transactions occurred on April 1, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025.

How many Alkermes (ALKS) shares did Craig C. Hopkinson sell and at what price?

He sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share. The sale involved multiple trades between $35.50 and $35.62, with detailed breakdowns available to the issuer, its security holders, or SEC staff upon request.

What options did Craig C. Hopkinson exercise in Alkermes (ALKS) stock?

He exercised Employee Stock Options covering 5,000 Ordinary Shares at an exercise price of $19.34 per share. The filing notes these options were fully vested in accordance with their terms and had an original expiration date of February 22, 2031.

How many Alkermes (ALKS) shares does Craig C. Hopkinson hold after these transactions?

Following the reported transactions, Craig C. Hopkinson directly holds 85,389 Ordinary Shares. This figure reflects his position after exercising 5,000 options and selling 9,000 shares on April 1, 2026 under the disclosed trading plan.

Were Craig C. Hopkinson’s Alkermes (ALKS) trades made under a Rule 10b5-1 plan?

Yes. Both the option exercise and the subsequent sale were effected under a Rule 10b5-1 trading plan. The filing states this plan was adopted by the reporting person on March 14, 2025, indicating the transactions were pre-arranged rather than discretionary.

Does the Alkermes (ALKS) Form 4 show any remaining derivative holdings for Craig C. Hopkinson?

The filing’s derivative summary is empty, indicating no remaining derivative positions are reported. The exercised options were fully vested, and after their conversion into 5,000 Ordinary Shares, only direct Ordinary Share holdings are shown for Hopkinson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 06:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/01/2026		M(1)		5,000	A	$19.34	94,389	D
Ordinary Shares	04/01/2026		S(2)		9,000	D	$35.5116(3)	85,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.34	04/01/2026		M(1)			5,000	(4)	02/22/2031	Ordinary Shares	5,000	$0	16,356	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.50 to $35.62. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)